BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 20202309)

  • 1. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
    Griffin AT; Peyrani P; Wiemken T; Arnold F
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
    Mykietiuk A; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
    Clin Infect Dis; 2005 Mar; 40(6):794-9. PubMed ID: 15736010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment for Legionnaires' disease. Macrolides or quinolones?].
    Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A
    Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Community-acquired pneumonia due to Legionella pneumophila serogroup 1. Study of 97 cases].
    Benito JR; Montejo JM; Cancelo L; Zalacaín R; López L; Fernández Gil de Pareja J; Alonso E; Oñate J
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):394-400. PubMed ID: 14525703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization.
    Plouffe JF; Breiman RF; Fields BS; Herbert M; Inverso J; Knirsch C; Kolokathis A; Marrie TJ; Nicolle L; Schwartz DB
    Clin Infect Dis; 2003 Dec; 37(11):1475-80. PubMed ID: 14614670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.
    Blázquez Garrido RM; Espinosa Parra FJ; Alemany Francés L; Ramos Guevara RM; Sánchez-Nieto JM; Segovia Hernández M; Serrano Martínez JA; Huerta FH
    Clin Infect Dis; 2005 Mar; 40(6):800-6. PubMed ID: 15736011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Community-Acquired Pneumonia Due to Legionella pneumophila Serogroup 9 Wherein Initial Treatment with Single-Dose Oral Azithromycin Appeared Useful.
    Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T; Fujii H; Hashimoto T; Nakajima H; Amemura-Maekawa J
    Jpn J Infect Dis; 2017 Nov; 70(6):660-662. PubMed ID: 28890505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of pneumonia caused by Legionella with azithromycin].
    Sánchez F; Mensa J; Martínez JA; Badia R; Albarracín M; Losa JE; Ruiz M; Marcos MA; Torres A; Soriano E
    Rev Esp Quimioter; 1998 Jun; 11(2):147-51. PubMed ID: 9795300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia.
    Grau S; Antonio JM; Ribes E; Salvadó M; Garcés JM; Garau J
    Int J Antimicrob Agents; 2006 Sep; 28(3):249-52. PubMed ID: 16870401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
    Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
    Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
    Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
    Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legionella: macrolides or quinolones?
    Pedro-Botet L; Yu VL
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():25-30. PubMed ID: 16669926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years.
    Viasus D; Di Yacovo S; Garcia-Vidal C; Verdaguer R; Manresa F; Dorca J; Gudiol F; Carratalà J
    Medicine (Baltimore); 2013 Jan; 92(1):51-60. PubMed ID: 23266795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
    Gacouin A; Le Tulzo Y; Lavoue S; Camus C; Hoff J; Bassen R; Arvieux C; Heurtin C; Thomas R
    Intensive Care Med; 2002 Jun; 28(6):686-91. PubMed ID: 12107671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.